|
2008 |
|
Prolastin DirectSM delivery program launched in Canada. |
|
2008 |
|
Precision Pharma Services merges into Talecris Biotherapeutics. |
|
2008 |
|
Talecris celebrates 20th anniversary of launch of Prolastin® Alpha1-Proteinase Inhibitor (Human). |
|
2007 |
|
Talecris honored as an Industry Week 2007 Best Plants Award Finalist. |
|
2007 |
|
Talecris initiates clinical development program evaluating plasmin for dissolving blood clots and restoring blood flow in legs. |
|
2006 |
|
Talecris announces the formation of Talecris Plasma Resources and the purchase of its own plasma collection centers. |
| 2006 |
|
Launch of Talecris Talents, an annual million-dollar grant program to fund basic and clinical research involving use of intravenous immunoglobulin. |
| 2006 |
|
Talecris expands into Canada (April 1) and Europe (December 1). |
| 2005 |
|
Talecris receives QSEAL certification from the Plasma Protein Therapeutics Association (PPTA). |
| 2005 |
|
Talecris Biotherapeutics established in United States, acquiring the contributed assets of the worldwide plasma business of Bayer BP and the additional fractionation capacity and contract manufacturing services of Precision Pharma Services.
|
| 2004 |
|
Bayer BP is first plasma fractionator to receive FDA approval for in-house nucleic acid testing (NAT) of human immunodeficiency virus (HIV).
|
| 2004 |
|
Launch of Gamunex® Immune Globulin Intravenous (Human), 10% Caprylate / Chromatography Purified. |
| 2003 |
|
Bayer BP uses innovative viral inactivation technology (caprylate) in the production of IGIV. |
| 2002 |
|
Bayer BP is first company in biological products industry to launch Tamper-Evident-Packaging (TEP). |
| 2001 |
|
Bayer BP develops Western Blot Assay methodology for testing plasma purification during the manufacture of therapeutic proteins, the first of its kind in the biological products industry.
|
| 2001 |
|
Melville, N.Y. facility purchased by Ampersand Ventures and renamed Precision Pharma Services. |
| 1999 |
|
Innovative drug distribution program created (now called Prolastin DirectSM) for alpha-1 patient; includes services of AlphaNet Coordinators.
|
| 1999 |
|
Clayton, N.C. facility fractionation capacity reaches 1.9 million liters per year. |
| 1995 |
|
Miles Inc. renamed Bayer Corporation. |
| 1992 |
|
Bayer AG merges its U.S. subsidiaries to form Miles, Inc. |
| 1988 |
|
Launch of Prolastin®, Alpha1- Proteinase Inhibitor (Human), first proteinase inhibitor product. |
| 1981 |
|
Miles Laboratories, Inc. is granted approval for the first liquid intravenous immune globulin (IGIV), Gamimune®, Immune Globulin Intravenous (Human).
|
| 1980 |
|
Precision Pharma Services predecessor New York Blood Center (Melville Biologics) facility in Melville, N.Y. is licensed by the FDA. |
| 1978 |
|
Bayer acquires Miles Laboratories, Inc. |
| 1974 |
|
Cutter acquired by Miles Laboratories, Inc. |
| 1974 |
|
Cutter completes Clayton, N.C. facility and begins producing product with a staff of 100 and a capacity of 375,000 liters per year.
|
| 1972 |
|
Cutter Laboratories breaks ground in Clayton, N.C.
|
| 1942 |
 |
Cutter Laboratories pioneers plasma fractionation and develops first blood product, albumin. |
